BIRC2/cIAP1 is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency

Cell Host and Microbe

Volumn 18, Issue 3, 2015, Pages 345-353

  Pache, Lars ^a   Dutra, Miriam S ^a   Spivak, Adam M ^b   Marlett, John M ^c   Murry, Jeffrey P ^c,h   Hwang, Young ^d   Maestre, Ana M ^e   Manganaro, Lara ^e   Vamos, Mitchell ^a   Teriete, Peter ^a   Martins, Laura J ^b   König, Renate ^a,f,g   Simon, Viviana ^e   Bosque, Alberto ^b   Fernandez Sesma, Ana ^e   Cosford, Nicholas D P ^a   Bushman, Frederic D ^d   Young, John A T ^c,i   Planelles, Vicente ^b   Chanda, Sumit K ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f PAUL EHRLICH INSTITUT   (Germany)

^g German Center for Infection Research (DZIF)   (Germany)

^h GILEAD SCIENCES   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC RNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; N [1 CYCLOHEXYL 2 [2 [4 (4 FLUOROBENZOYL) 2 THIAZOLYL] 1 PYRROLIDINYL] 2 OXOETHYL] 2 (METHYLAMINO)PROPANAMIDE; PANOBINOSTAT; PEPTIDOMIMETIC AGENT; SBI 0637142; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TRANSCRIPTION FACTOR RELA; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE BIRC2; UNCLASSIFIED DRUG; VIRUS MESSENGER RNA; VIRUS RNA; VORINOSTAT; BIRC2 PROTEIN, HUMAN; HYDROXAMIC ACID; INDOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; OLIGOPEPTIDE; SMAC PEPTIDE;

ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; JURKAT CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; TRANSCRIPTION INITIATION; VIRAL CLEARANCE; VIRUS CARRIER; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; GENE EXPRESSION REGULATION, VIRAL; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; HYDROXAMIC ACIDS; INDOLES; INHIBITOR OF APOPTOSIS PROTEINS; OLIGOPEPTIDES; TRANSCRIPTION, GENETIC; UBIQUITIN-PROTEIN LIGASES; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84941275484     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2015.08.009     Document Type: Article

References (35)

1. S. Agarwal, J. Harada, J. Schreifels, P. Lech, B. Nikolai, T. Yamaguchi, S.K. Chanda, and N.V. Somia Isolation, characterization, and genetic complementation of a cellular mutant resistant to retroviral infection Proc. Natl. Acad. Sci. USA 103 2006 15933 15938
2. L. Bai, D.C. Smith, and S. Wang Small-molecule SMAC mimetics as new cancer therapeutics Pharmacol. Ther. 144 2014 82 95
3. S. Basak, H. Kim, J.D. Kearns, V. Tergaonkar, E. O'Dea, S.L. Werner, C.A. Benedict, C.F. Ware, G. Ghosh, I.M. Verma, and A. Hoffmann A fourth IkappaB protein within the NF-kappaB signaling module Cell 128 2007 369 381
4. A. Bosque, and V. Planelles Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells Blood 113 2009 58 65
5. L.V. Britanova, V.J. Makeev, and D.V. Kuprash In vitro selection of optimal RelB/p52 DNA-binding motifs Biochem. Biophys. Res. Commun. 365 2008 583 588
6. C.K. Bullen, G.M. Laird, C.M. Durand, J.D. Siliciano, and R.F. Siliciano New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo Nat. Med. 20 2014 425 429
7. J.C. Burnett, K.I. Lim, A. Calafi, J.J. Rossi, D.V. Schaffer, and A.P. Arkin Combinatorial latency reactivation for HIV-1 subtypes and variants J. Virol. 84 2010 5958 5974
8. D.A. Donahue, and M.A. Wainberg Cellular and molecular mechanisms involved in the establishment of HIV-1 latency Retrovirology 10 2013 11
9. D. Finlay, M. Vamos, M. González-López, R.J. Ardecky, S.R. Ganji, H. Yuan, Y. Su, T.R. Cooley, C.T. Hauser, K. Welsh, and et al. Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs Mol. Cancer Ther. 13 2014 5 15
10. S. Fulda, and D. Vucic Targeting IAP proteins for therapeutic intervention in cancer Nat. Rev. Drug Discov. 11 2012 109 124
11. A.J. Fusco, D.B. Huang, D. Miller, V.Y. Wang, D. Vu, and G. Ghosh NF-kappaB p52:RelB heterodimer recognizes two classes of kappaB sites with two distinct modes EMBO Rep. 10 2009 152 159
12. B. Groschel, and F. Bushman Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus J. Virol. 79 2005 5695 5704
13. S. Gummuluru, and M. Emerman Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines J. Virol. 73 1999 5422 5430
14. J.R. Infante, E.C. Dees, A.J. Olszanski, S.V. Dhuria, S. Sen, S. Cameron, and R.B. Cohen Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors J. Clin. Oncol. 32 2014 3103 3110
15. J.J. Keats, R. Fonseca, M. Chesi, R. Schop, A. Baker, W.J. Chng, S. Van Wier, R. Tiedemann, C.X. Shi, M. Sebag, and et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma Cancer Cell 12 2007 131 144
16. R. König, Y. Zhou, D. Elleder, T.L. Diamond, G.M. Bonamy, J.T. Irelan, C.Y. Chiang, B.P. Tu, P.D. De Jesus, C.E. Lilley, and et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication Cell 135 2008 49 60
17. G.M. Laird, C.K. Bullen, D.I. Rosenbloom, A.R. Martin, A.L. Hill, C.M. Durand, J.D. Siliciano, and R.F. Siliciano Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations J. Clin. Invest. 125 2015 1901 1912
18. L. Manganaro, L. Pache, T. Herrmann, J. Marlett, Y. Hwang, J. Murry, L. Miorin, A.T. Ting, R. König, A. García-Sastre, and et al. Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner J. Virol. 88 2014 7528 7540
19. D.M. Margolis Mechanisms of HIV latency: an emerging picture of complexity Curr. HIV/AIDS Rep. 7 2010 37 43
20. D.M. Margolis Histone deacetylase inhibitors and HIV latency Curr. Opin. HIV AIDS 6 2011 25 29
21. R.J. Morgan Jr., L. Leong, W. Chow, D. Gandara, P. Frankel, A. Garcia, H.J. Lenz, and J.H. Doroshow Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study Invest. New Drugs 30 2012 723 728
22. G. Nabel, and D. Baltimore An inducible transcription factor activates expression of human immunodeficiency virus in T cells Nature 326 1987 711 713
23. D.G. Nguyen, H. Yin, Y. Zhou, K.C. Wolff, K.L. Kuhen, and J.S. Caldwell Identification of novel therapeutic targets for HIV infection through functional genomic cDNA screening Virology 362 2007 16 25
24. R. Pearson, Y.K. Kim, J. Hokello, K. Lassen, J. Friedman, M. Tyagi, and J. Karn Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency J. Virol. 82 2008 12291 12303
25. T.A. Rasmussen, M. Tolstrup, A. Winckelmann, L. Ostergaard, and O.S. Søgaard Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials Hum. Vaccin. Immunother. 9 2013 790 799
26. N. Sakane, H.S. Kwon, S. Pagans, K. Kaehlcke, Y. Mizusawa, M. Kamada, K.G. Lassen, J. Chan, W.C. Greene, M. Schnoelzer, and M. Ott Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1) PLoS Pathog. 7 2011 e1002184
27. V.F. Shih, R. Tsui, A. Caldwell, and A. Hoffmann A single NFκB system for both canonical and non-canonical signaling Cell Res. 21 2011 86 102
28. A.M. Spivak, A. Bosque, A.H. Balch, D. Smyth, L. Martins, and V. Planelles Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+ T Cells from Aviremic Patients Antimicrob. Agents Chemother. 2015 10.1128/AAC.01077-15 AAC.01077-15
29. S.C. Sun The noncanonical NF-κB pathway Immunol. Rev. 246 2012 125 140
30. M. Vamos, K. Welsh, D. Finlay, P.S. Lee, P.D. Mace, S.J. Snipas, M.L. Gonzalez, S.R. Ganji, R.J. Ardecky, S.J. Riedl, and et al. Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP ACS Chem. Biol. 8 2013 725 732
31. D.G. Wei, V. Chiang, E. Fyne, M. Balakrishnan, T. Barnes, M. Graupe, J. Hesselgesser, A. Irrinki, J.P. Murry, G. Stepan, and et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing PLoS Pathog. 10 2014 e1004071
32. S.A. Williams, L.F. Chen, H. Kwon, C.M. Ruiz-Jarabo, E. Verdin, and W.C. Greene NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation EMBO J. 25 2006 139 149
33. V.C. Wong, L.E. Fong, N.M. Adams, Q. Xue, S.S. Dey, and K. Miller-Jensen Quantitative evaluation and optimization of co-drugging to improve anti-HIV latency therapy Cell. Mol. Bioeng. 7 2014 320 333
34. S. Xing, and R.F. Siliciano Targeting HIV latency: pharmacologic strategies toward eradication Drug Discov. Today 18 2013 541 551
35. B.J. Zarnegar, Y. Wang, D.J. Mahoney, P.W. Dempsey, H.H. Cheung, J. He, T. Shiba, X. Yang, W.C. Yeh, T.W. Mak, and et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK Nat. Immunol. 9 2008 1371 1378